Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × trastuzumab duocarmazine × Clear all
NCT04205630 2024-05-30

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Byondis B.V.

Phase 2 Completed
64 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡